130 related articles for article (PubMed ID: 11905263)
1. Antitrust: medical device corporation liable for violating FTC order.
Montgomery R
J Law Med Ethics; 2002; 30(1):122-3. PubMed ID: 11905263
[No Abstract] [Full Text] [Related]
2. The FTC v. Actavis roadmap: a guide to properly applying the rule of reason standard in reverse payment cases.
Sharkey N
J Leg Med; 2014; 35(3):445-66. PubMed ID: 25207633
[No Abstract] [Full Text] [Related]
3. The wake of FTC v. Actavis: practical implications on the pharmaceutical industry.
Ritter M; Tempesta J; Ragusa P
Pharm Pat Anal; 2014 Jul; 3(4):345-7. PubMed ID: 25291307
[No Abstract] [Full Text] [Related]
4. FTC, Justice antitrust policies right on target.
Kenyon MK
Mod Healthc; 1996 Feb; 26(7):83. PubMed ID: 10154740
[No Abstract] [Full Text] [Related]
5. FTC decides on two consolidations.
Scott L
Mod Healthc; 1995 Mar; 25(10):52. PubMed ID: 10140402
[No Abstract] [Full Text] [Related]
6. The Role of Regulatory Agencies and Intellectual Property: Part II.
Noonan KE
Cold Spring Harb Perspect Med; 2015 Mar; 5(7):a020834. PubMed ID: 25775920
[TBL] [Abstract][Full Text] [Related]
7. Brand-name drug manufacturers risk antitrust violations by slowing generic production through patent layering.
Paine CS
Seton Hall Law Rev; 2003; 33(2):479-510. PubMed ID: 12715807
[No Abstract] [Full Text] [Related]
8. Pharmaceutical patent settlements: the antitrust risks.
Balto DA
Food Drug Law J; 2000; 55(3):321-41. PubMed ID: 11824464
[No Abstract] [Full Text] [Related]
9. Life, death, and monopoly rights in a democratic society.
Smith SJ
Am J Bioeth; 2002; 2(3):43-4. PubMed ID: 12230856
[No Abstract] [Full Text] [Related]
10. US market: 2008 priorities.
Novelli T
Med Device Technol; 2008; 19(3):58. PubMed ID: 18557412
[No Abstract] [Full Text] [Related]
11. Medical staff privileges and the antitrust laws: a view from the Federal Trade Commission.
Horoschak MJ
Med Staff Couns; 1992; 6(2):17-24. PubMed ID: 10116790
[TBL] [Abstract][Full Text] [Related]
12. Settlements between brand and generic pharmaceutical companies: a reasonable antitrust analysis of reverse payments.
Yvon AM
Fordham Law Rev; 2006 Dec; 75(3):1883-912. PubMed ID: 17312596
[No Abstract] [Full Text] [Related]
13. An economic and antitrust analysis of the distribution of medical products.
Celnicker AC
Am J Law Med; 1990; 16(4):499-523. PubMed ID: 2102059
[TBL] [Abstract][Full Text] [Related]
14. Genetic patents: gatekeeper to the promised cures.
Westin LP
Thomas Jefferson Law Rev; 2002; 25(1):271-99. PubMed ID: 15164741
[No Abstract] [Full Text] [Related]
15. Recent Supreme Court decisions and licensing power.
Giordano-Coltart J; Calkins CW
Nat Biotechnol; 2008 Feb; 26(2):183-5. PubMed ID: 18259170
[TBL] [Abstract][Full Text] [Related]
16. Public positions on antitrust changes.
West D; Costello M; Boyle K
Adm Radiol J; 1996 Jun; 15(6):14-6, 20. PubMed ID: 10159366
[No Abstract] [Full Text] [Related]
17. Does your physician network violate antitrust law?. Interview by Michael Pretzer.
Pitofsky R
Med Econ; 1996 Oct; 73(19):68-70, 73-6, 79. PubMed ID: 10162456
[No Abstract] [Full Text] [Related]
18. Color as a trademark under the Lanham Act: confusion in the circuits and the need for uniformity.
Carraway JC
Law Contemp Probl; 1994; 57(4):243-79. PubMed ID: 10140661
[No Abstract] [Full Text] [Related]
19. The physician cartel--potential hospital federal antitrust liability in class-based denial of staff privileges to clinical psychologists.
Rypma JA
Spec Law Dig Health Care Law; 1991 Jul; (149):7-33. PubMed ID: 10112686
[No Abstract] [Full Text] [Related]
20. Gene therapy and the 14th century Karelians.
Jex EA; Inglefield DL; Christini MA
Nat Biotechnol; 1997 Apr; 15(4):299. PubMed ID: 9094109
[No Abstract] [Full Text] [Related]
[Next] [New Search]
